Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis.

Departments of Pediatrics and Child Health, Tygerberg Hospital, Tygerberg, South Africa.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.57). 01/2001; 44(12):3285-7. DOI: 10.1128/AAC.44.12.3285-3287.2000
Source: PubMed

ABSTRACT The early bactericidal activity of the aminoglycoside paromomycin (aminosidine) in doses of 7.5 and 15 mg/kg of body weight was measured in 22 patients with previously untreated smear-positive pulmonary tuberculosis. The fall in log(10) CFU per milliliter of sputum per day during the first 2 days of treatment for 7 patients receiving a paromomycin dosage of 7.5 mg/kg/day was 0.066, with a standard deviation (SD) of 0.216 and confidence limits from -0.134 to 0.266, and that for 15 patients receiving 15 mg/kg/day was 0.0924, with an SD of 0.140 and confidence limits from 0.015 to 0.170. The difference between the mean and zero was not significant for the 7. 5-mg/kg dose group but was significant for the 15-mg/kg dose group (t = 2.55, P = 0.023). Since paromomycin has no cross-resistance with streptomycin and has no greater toxicity than other aminoglycosides, these results suggest that it has the potential to substitute for streptomycin in antituberculosis regimens and may be a particularly valuable addition to the drug armamentarium for the management of multidrug-resistant tuberculosis.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Blastocystis is an emerging protistan parasite of controversial pathogenesis. Although metronidazole (Mz) is standard therapy for Blastocystis infections, there have been accumulating reports of treatment failure, suggesting the existence of drug-resistant isolates. Furthermore, very little is known about Blastocystis susceptibility to standard antimicrobials. In the present study, we established resazurin and XTT viability microassays for Blastocystis spp. belonging to subtypes 4 and 7, both of which have been suggested to represent pathogenic zoonotic subtypes. The optimized resazurin assay was used to screen a total of 19 compounds against both subtypes. Interestingly, subtype 7 parasites were resistant to Mz, a 1-position-substituted 5-nitroimidazole (5-NI), while subtype 4 parasites were sensitive. Some cross-resistance was observed to tinidazole, another 1-position 5-NI. Conversely, subtype 4 parasites were resistant to emetine, while subtype 7 parasites were sensitive. Position 2 5-NIs were effective against both subtypes, as were ornidazole, nitazoxanide, furazolidone, mefloquine, quinicrine, quinine, cotrimoxazole (trimethoprim-sulfamethoxazole), and iodoacetamide. Both subtypes were resistant to chloroquine, doxycycline, paromomycin, ampicillin, and pyrimethamine. This is the first study to report extensive variations in drug sensitivities among two clinically important subtypes. Our study highlights the need to reevaluate established treatment regimens for Blastocystis infections and offers clear new treatment options for Mz treatment failures.
    Antimicrobial Agents and Chemotherapy 02/2011; 55(2):637-48. · 4.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Three new chiral NHC–rhodium complexes have been prepared from the reactions between [Rh(COD)Cl]2, NaOAc, KI, and dibenzimidazolium salts 3, 4 or 5, which are derived from (S)-2,2′-diamino-1,1′-binaphthyl. The steric and electronic effects of the ligand play an important role in the complex formation. For example, treatment of pyridine substituted dibenzimidazolium salts 3 or 4 with 0.5 equiv of [Rh(COD)Cl]2 in the presence of NaOAc and KI in CH3CN at 85 °C gives the chiral Rh(III) complexes 6 and 7, respectively. However, under similar reaction conditions, pyridine-N-oxide substituted dibenzimidazolium salt 5 affords a binuclear Rh(I) complex 8. All compounds have been characterized by various spectroscopic techniques, and elemental analyses. The solid-state structures of compounds 4–8 have been further confirmed by X-ray diffraction analyses. Rhodium complexes 6–8 show good catalytic activity for the asymmetric hydrosilylation of acetophenone with moderate ee values.
    Journal of Organometallic Chemistry - J ORGANOMET CHEM. 01/2011; 696(23):3714-3720.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Early bactericidal activity studies measure the ability of antituberculosis treatments to reduce the burden of Mycobacterium tuberculosis in sputum specimens collected overnight from smear-positive pulmonary tuberculosis patients during the first 14 days of therapy. This confirms the efficacy of novel agents or drug combinations in human patients, allows comparison of different drug dosages and a preliminary assessment of the drugs' pharmacokinetics and toxicity in closely observed patients. In the past few years several novel antituberculosis agents have demonstrated significant early bactericidal activity and progressed to studies of longer duration. Most recently the early bactericidal activity of drug combinations was found to be similar to results predicted by murine studies. This may contribute to expediting the future progress of drug evaluation.
    Expert Review of Anticancer Therapy 01/2014; · 3.22 Impact Factor


Available from